{"groups":[{"description":"Subjects received at least one dose of study treatment","id":"FG000","title":"All Study Subjects"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lack of Efficacy"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"39"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"25"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"14"}],"type":"NOT COMPLETED"}],"title":"Overall Study (Until End of Surgery)"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Adverse Event"}],"milestones":[{"achievements":[{"comment":"The participants were prescribed adjuvant chemotherapy based on the surgical pathology report included.","groupId":"FG000","numSubjects":"21"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"8"}],"type":"NOT COMPLETED"}],"title":"Adjuvant Chemotherapy"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Adverse Event"}],"milestones":[{"achievements":[{"comment":"The participants were prescribed adjuvant durvalumab based on the surgical pathology report included.","groupId":"FG000","numSubjects":"35"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"25"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"NOT COMPLETED"}],"title":"Adjuvant Durvalumab"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Adverse Event"}],"milestones":[{"achievements":[{"comment":"The participants were prescribed adjuvant radiotherapy based on the surgical pathology report included.","groupId":"FG000","numSubjects":"21"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"14"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Adjuvant Radiotherapy"}],"preAssignmentDetails":"A total of 44 participants consented, but 5 were deemed to be ineligible, and 39 subjects enrolled in the study; 37 out of 39 subjects completed neoadjuvant therapy, and 2 subjects were off the treatment due to toxicity; 35 out of 37 subjects underwent surgery at study centers, one subject had surgery elsewhere, and one subject declined the surgery. Subjects received adjuvant therapy based on surgical pathology results and treatment progress was submitted separately.","recruitmentDetails":"Participants were recruited from 12/19/2017 through 11/09/2021 at 4 cancer centers in the United States."}